View Article

  • NSAID Induced Acute Kidney Injury (AKI): A Case Study
  • 1Pharm D Intern (Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India) 
    2Fifth Pharm D (Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India) 
    3 Consultant Gastroenterologist (NIMS Medicity, Neyyattinkara, kerala, India) 
    4 Principal, HOD (Department of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India) 
    5Associate professor (Department of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India)
     

Abstract

Acute Kidney Injury, previously known as Acute Renal Failure, denotes a sudden and often reversible reduction in the kidney function, measured by increased creatinine or decreased urine volume. Although immediately after a renal insult, blood urea nitrogen or creatinine levels may be within the normal range, the only sign of Acute Kidney Injury may be a decline in the urine output. Acute Kidney Injury can lead to the accumulation of water, sodium, and other metabolic products. The crude odds ratio for Kidney Injury in non-steroidal anti inflammatory drug users compared to non-users ranged from 1.12-5.25 and was greater than 1. Renal cell damage is more prominent in patients taking non-steroidal anti inflammatory drugs. The major etiological factors contributing to Acute Kidney Injury are infections, drug induction, obstructive uropathy, dehydration, snake bite, cardio renal syndrome. The current case report features a patient who was admitted to the Gastroenterology department from outpatient basis due to an elevation in her serum creatinine level (4.7 mg/dL).

Keywords

Blood Urea Nitrogen, NSAIDs, Cyclooxygenase, Hepato Renal Syndrome, Drug-induced Acute Kidney Injury.

Introduction

Non steroidal anti- inflammatory drugs (NSAIDs) are one of the most commonly used Over the Counter (OTC) drugs. NSAIDs exert their anti- inflammatory effect via Cyclooxygenase (COX) inhibition. Their common adverse effects include gastrointestinal ulcers, cardiac toxicity, bleeding diathesis, allergic reactions and renal complications, with acute kidney injury [2, 3] being the most common form of NSAIDs – induced renal injury. NSAIDs can reduce renal blood flow, cause tubular obstruction through crystal deposition, and induce direct cytotoxicity and cell- mediated immune injury mechanisms leading to the occurrence of AKI [4]. Other manifestations include hypertension, oedema, hyponatremia, hyperkalemia, nephritic syndrome, papillary necrosis and interstitial nephritis. The major signs and symptoms of AKI include swelling on legs, ankles, and around the eyes, fatigue or tiredness, decreased urine output, confusion, lower abdominal pain. These incidences of AKI are mainly determined as per the stage which it was belonged to. Mostly AKI has 3 stages [5] (Table 1). Etiological factors contributing to AKI differs and which includes infections, cardio renal syndrome, drug use, obstructive condition of the urinary tract, dehydration, etc (Figure 1). In this article we report a known case of CLD who developed AKI (Grade III) by taking NSAIDs. Thereby rapidly withdraw the suspected drug which causes the reaction.



    Image

Table 1: Staging of Acute Kidney Injury according to current kidney Disease Improving Global Outcomes definition.


 



    Image

Figure 1: Etiology of Acute kidney Injury (AKI)


CASE REPORT:

A 53-year-old female patient came to the Gastroenterology department for her routine review. On evaluation, serum Creatinine shows acute elevation (4.7mg/dL). She had a past medical history of Chronic Liver Disease (CLD) for 8 months and Hypothyroidism for the past 2 years. And was on medical treatment with TAB. URSODEOXYCHOLIC ACID 300mg, PROTEIN SUPPLEMENTS 30gm, and DIETARY SUPPLEMENTS 500+400mg, HEME IRON POLYPEPTIDES 12mg, TAB. THYROXINE 100mcg. She was admitted to the hospital with the chief complaints of abdominal pain and pedal oedema 8 months back. And show alterations in renal function and thought to be as Hepato Renal Syndrome (HRS). On taking her family and social history, came to know about the intake of ACECLOFENAC and PARACETAMOL tablet for toothache. Thus concluded this case as NSAID induced AKI. She was admitted 12 days in the hospital.  Admission examination showed: Blood pressure of 120/80mmHg, heart rate of 72beats/min, no abnormalities in the auscultation of the lungs, Oxygen saturation at rate of 97 %, no murmur in the heart, pallor positive, no abdominal tenderness. The patient was anaemic. ESR, SGOT, SGPT, ALP, Urinary epithelial cells and pus cells were found to be elevated than normal limits. Albumin level monitored on LFT was below the limit. It is declined to 2.8 mg/dL. Urea (58 mg/dL) and serum Creatinine (4.7mg/dL) on the day of admission was declined. Due to the elevation of urinary pus cells and epithelial cells, urine culture is done and it is sterile. USG of abdomen and pelvis was taken, and it shows mildly coarsened hepatic echo texture with Splenomegaly and bilateral Grade I parenchyma echoes. Serum urea, Creatinine and levels were monitored for 11 days for her hospital stay (Table 2). PTINR was monitored for 4 days (Table 3).



    Image

(Table 2): Determination of Serum Urea and Creatinine for the first 11 days of hospital stay




    Image

(Table 3): Determination of PTINR value on Day 2, Day 6, Day 7, and Day 8


She was treated with vasopressin agonist (INJ. TERLIPRESSIN 1mg), Proton pump inhibitor (TAB. PANTOPRAZOLE 40mg), Hepatoprotective agent (TAB. UDILIV 300mg), and Rifamycin antibiotic (TAB. RIFAXIMIN 550mg). During nephrologist’s consultation, it was advised to give ALBUMIN – TERLIPRESSIN infusion. So INJ TERLIPRESSIN changed from 1mg Q6H to BD. Also added TAB. SODIUM BICARBONATE 500mg, TAB. FOLIC ACID 5mg, and Inj. ACETYL CYSTEINE 1.2gm, and Inj. HUMAN ALBUMIN was given on daily basis. Potassium and sodium level declination found on the eight day and was corrected with Ivf. NORMAL SALINE 500ml with Inj POTASSIUM CHLORIDE 40mEq. Creatinine levels gradually declined. She was clinically stable and discharged after 12 days of hospital stay.

DISCUSSION:

The aetiology of AKI is conceptually classified into three general categories: Pre-renal, Intra-renal and Post-renal (Table 4) [6]. This patient was admitted with elevated serum Creatinine (4.7mg/dL). The points in favour NSAID induced AKI was reduced urine output, history of taking NSAIDs, declined serum Creatinine. ALBUMIN infusion was given to correct hypoalbuminemia. Patient was admitted for 12 days in the hospital and was clinically better. On twelfth day, her serum Urea and Creatinine were 40 and 2.3 respectively.  Discontinuation of the drug is important in case of drug induced diseases. Cirrhotic patients are more prone to develop drug induced AKI than normal individuals. Here the drug was stopped due to renal impairment. NSAIDs have an inhibitory effect on both COX – 1 and COX – 2, that is enzymes that inhibit Prostaglandin (PG) synthesis. Both forms of this isoenzyme are found in the kidney [7]. Blocking one or both of these enzymes can defect different kidney functions [8,9,10]. COX – 2 derived PGs have profound effects on renal homeostasis, suggesting that selective COX – 2 inhibitors such as CELECOXIB may have the same potential for renal adverse effects as traditional non- selective NSAIDs, especially in clinical situations associated with a renal impairment such as sodium depletion, hypovolemia, cirrhosis, heart failure, Nephrotic syndrome, and CKD.



    Image

Table 4: Medical causes of Acute Kidney Injury (AKI)

 

CONCLUSION:

Acute Kidney Injury (AKI) is a global public health concern associated with high morbidity, mortality, and healthcare costs. It is more common among cirrhotic or CLD patients than normal individuals. For these, treatments are needed to reduce the high morbidity and mortality and improve recovery of renal function; however, the multifactorial aetiology of AKI and the complicated clinical course of the patient have created challenges in the search for pharmacological agents that work [11.12]. Here the patient is presented with elevation in serum Creatinine levels on blood examination. The Ultrasound scan of abdomen and pelvis shows Grade I renal parenchyma echoes and mildly coarsened hepatic echo texture. Patient started with proton pump inhibitors, antibiotics, liver protectants, protein supplementation. Patient had past history of Hypothyroidism for past 2 years and taking THYRONORM and CLD for past 8 months. Her own medicines are continued on her hospital stay. In conclusion, treatment of AKI induced by ACECLOFENAC and PARACETAMOL was effective depending upon its severity. The first step physicians put forward is the discontinuation of the drug.

REFERENCES:

  1. Levey AS, James MT. Acute Kidney Injury. Annuals of internal medicine. 2017 Nov 7; 167(9):ITC66-80.
  2. Dubois RN, Abramson SB, Crofford C, et al. Cyclooxygenase in biology and disease. Fasebj 1998; 12(12):1063-72.
  3. Wongrakparish S, Wongrapanich A, Melhadot K, Rangaswami J. A comprehensive review of non – steroidal anti – inflammatory drug use in the elderly. Aging Dis 2018; 9(1):143-150.
  4. Zhang X, Donnan PT, Bell S, Guthire B. Non – steroidal anti – inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: Systematic review and meta- analysis. BMC nephrology 2017 Dec; 18(1):1-2.
  5. Griffin BR, Teixeira JP, Ambruso S, Bronsert M, Pal JD, Cleveland TC, Reece TB, Fullerton DA, Faubel S, Aftab M. The journal of Thoracic and Cardiovascular Surgery. 2021 April 1; 161(4):1346- 55.
  6. Turgut F, Awad AS, Abdel- Rahman EM. Acute Kidney Injury; Medical causes and pathogenesis. Journal of Clinical medicine. 2023 Jan 3:12(1):375.
  7. Drozdzal S, Lechowicz K, Rosik J, et al. Kidney damage from non – steroidal anti – inflammatory drugs – Myth or truth? Review of selected literature. Pharmacology research and perspective, 9(4), p.e00817.
  8. Khan S, Andrews KL, Chin – Dusting JPF. Cyclooxygenase 9COX) inhibitors and cardiovascular risk: Is non – steroidal anti – inflammatory drugs really anti – inflammatory? Int JMol Sci. 2019; 20: 4262.
  9. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison – Bernard LM. Mitchell KD. Paracrine regulation of the renal micro circulation. Physiol Rev. 1996; 76: 425- 536.
  10. Villa E, Garcia Robles R, Haas J, Romero JC. Comparative effect of PGE2 and PGI2 in renal function. Hypertens. 1997; 30: 664- 666.
  11. Horl WH. Non steroidal anti- inflammatory drug and the kidney. Pharmaceuticals. 2010; 3: 2291-2321.
  12. Zuk A, Bonventre JV. Acute Kidney Injury, Annual review of medicine. 2016Jan 14; 67: 293- 301.

Reference

  1. Levey AS, James MT. Acute Kidney Injury. Annuals of internal medicine. 2017 Nov 7; 167(9):ITC66-80.
  2. Dubois RN, Abramson SB, Crofford C, et al. Cyclooxygenase in biology and disease. Fasebj 1998; 12(12):1063-72.
  3. Wongrakparish S, Wongrapanich A, Melhadot K, Rangaswami J. A comprehensive review of non – steroidal anti – inflammatory drug use in the elderly. Aging Dis 2018; 9(1):143-150.
  4. Zhang X, Donnan PT, Bell S, Guthire B. Non – steroidal anti – inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: Systematic review and meta- analysis. BMC nephrology 2017 Dec; 18(1):1-2.
  5. Griffin BR, Teixeira JP, Ambruso S, Bronsert M, Pal JD, Cleveland TC, Reece TB, Fullerton DA, Faubel S, Aftab M. The journal of Thoracic and Cardiovascular Surgery. 2021 April 1; 161(4):1346- 55.
  6. Turgut F, Awad AS, Abdel- Rahman EM. Acute Kidney Injury; Medical causes and pathogenesis. Journal of Clinical medicine. 2023 Jan 3:12(1):375.
  7. Drozdzal S, Lechowicz K, Rosik J, et al. Kidney damage from non – steroidal anti – inflammatory drugs – Myth or truth? Review of selected literature. Pharmacology research and perspective, 9(4), p.e00817.
  8. Khan S, Andrews KL, Chin – Dusting JPF. Cyclooxygenase 9COX) inhibitors and cardiovascular risk: Is non – steroidal anti – inflammatory drugs really anti – inflammatory? Int JMol Sci. 2019; 20: 4262.
  9. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison – Bernard LM. Mitchell KD. Paracrine regulation of the renal micro circulation. Physiol Rev. 1996; 76: 425- 536.
  10. Villa E, Garcia Robles R, Haas J, Romero JC. Comparative effect of PGE2 and PGI2 in renal function. Hypertens. 1997; 30: 664- 666.
  11. Horl WH. Non steroidal anti- inflammatory drug and the kidney. Pharmaceuticals. 2010; 3: 2291-2321.
  12. Zuk A, Bonventre JV. Acute Kidney Injury, Annual review of medicine. 2016Jan 14; 67: 293- 301.

Photo
Dhanya Dharman
Corresponding author

Associate professor, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Trivandrum

Photo
Adithya S. L.
Co-author

Pharm D Intern (Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India)

Photo
Swaminath G. Iyer
Co-author

Fifth Pharm D (Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India)

Photo
Neehar M. Shanavas
Co-author

Consultant Gastroenterologist (NIMS Medicity, Neyyattinkara, kerala, India)

Photo
Shaiju S. Dharan
Co-author

Principal, HOD, Department of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram

Adithya S. L., Swaminath G. Iyer, Neehar M. Shanavas, Shaiju S. Dharan, Dhanya Dharman, NSAID Induced Acute Kidney Injury (AKI): A Case Study, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 3, 1262-1267. https://doi.org/10.5281/zenodo.10899139

More related articles
Insights into immune thrombocytopenic purpura: a r...
Dhanya Dharman , Ahalya U, Praveena R Prasad, Shaiju S Dharan, ...
Exploring The Pharmacognostical Attributes Of Barl...
Monisha T, Vijaya Bharathi R., Muthusamy P., Radha R., Senthilnat...
Optimizing Herbal Lozenges: Formulation Techniques...
V. Anitha, L. Gopi, R. Aishwarya, L. Akash, A. Afroze, A. Abdulla...
Transferosomes, Revolutionizing NSAIDS Delivery For Improved Therapeutic Efficac...
Anjitha M, K. Selvaraju, N. L. Gowrishankar, Athulya Prasad, Arun Giri Raj. V, Shabna. S, ...
Regulating Artificial Intelligence: Developments And Challenges...
Durga Chavali, Biju Baburajan, Ashokkumar Gurusamy, Vinod Kumar Dhiman, Siri Chandana Katari, ...
A Study On Antimicrobial Activity Of Lantana Camara...
Anshika Rathore , B. N. Birla , Vivek Yadav , Aman Karma , Sonali Patidar , ...
Related Articles
The Profound Impact Of Air Pollution On Human Health...
Hema Arya, Yash Sharma , Yash Varshney , Jannat Ul Firdaus, ...
Formulation Evaluation & Development Of Brain Boosting Herbal Chocolate...
Abhishek S. Amrutkar, Anurag C. Kumavat, Avez V. Shaikh, Ashok L. Bhise, Dr. Swapnil D. Deo, Dr. Gaj...
Analytical Method Development And Validation For The Estimation Of Azelnidipine ...
Akanksha D. Punekar, Sonali A. Waghmare, Aaditi S. Punekar, ...
Insights into immune thrombocytopenic purpura: a rare hematological disorder ...
Dhanya Dharman , Ahalya U, Praveena R Prasad, Shaiju S Dharan, ...
More related articles
Insights into immune thrombocytopenic purpura: a rare hematological disorder ...
Dhanya Dharman , Ahalya U, Praveena R Prasad, Shaiju S Dharan, ...
Exploring The Pharmacognostical Attributes Of Barleria Cristata: A Comprehensive...
Monisha T, Vijaya Bharathi R., Muthusamy P., Radha R., Senthilnathan S., Kaviyarasi M., ...
Optimizing Herbal Lozenges: Formulation Techniques and Efficacy Evaluation...
V. Anitha, L. Gopi, R. Aishwarya, L. Akash, A. Afroze, A. Abdullah, ...
Insights into immune thrombocytopenic purpura: a rare hematological disorder ...
Dhanya Dharman , Ahalya U, Praveena R Prasad, Shaiju S Dharan, ...
Exploring The Pharmacognostical Attributes Of Barleria Cristata: A Comprehensive...
Monisha T, Vijaya Bharathi R., Muthusamy P., Radha R., Senthilnathan S., Kaviyarasi M., ...
Optimizing Herbal Lozenges: Formulation Techniques and Efficacy Evaluation...
V. Anitha, L. Gopi, R. Aishwarya, L. Akash, A. Afroze, A. Abdullah, ...